Advertisement
New Zealand markets close in 5 hours 33 minutes
  • NZX 50

    11,839.81
    -32.83 (-0.28%)
     
  • NZD/USD

    0.6163
    -0.0008 (-0.14%)
     
  • ALL ORDS

    8,002.50
    +39.40 (+0.49%)
     
  • OIL

    77.79
    -0.83 (-1.06%)
     
  • GOLD

    2,318.40
    +0.40 (+0.02%)
     

Here's Why Astrazeneca (AZN) is a Strong Value Stock

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors.

While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks based on value, growth, and/or momentum characteristics.

Why Investors Should Pay Attention to This Value Stock

Value investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, and Price/Cash Flow, the Value Style Score identifies the most attractive and most discounted stocks.

ADVERTISEMENT

Astrazeneca (AZN)

AstraZeneca plc, headquartered in London, UK, is one of the largest biopharmaceutical companies in the world. AstraZeneca was formed on Apr 6, 1999, through the merger of Sweden’s Astra AB and UK’s Zeneca Group plc. AstraZeneca’s business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.

AZN is a Zacks Rank #3 (Hold) stock, with a Value Style Score of B and VGM Score of A. Shares are currently trading at a forward P/E of 19.7X for the current fiscal year compared to the Large Cap Pharmaceuticals industry's P/E of 14.6X. Additionally, AZN has a PEG Ratio of 1.5 and a Price/Cash Flow ratio of 14.3X. Value investors should also note AZN's Price/Sales ratio of 5.2X.

Value investors don't just pay attention to a company's valuation ratios; positive earnings play a crucial role, too. Four analysts revised their earnings estimate upwards in the last 60 days for fiscal 2023. The Zacks Consensus Estimate has increased $0.08 to $3.69 per share. AZN has an average earnings surprise of 8.1%.

Investors should take the time to consider AZN for their portfolios due to its solid Zacks Ranks, notable earnings and valuation metrics, and impressive Value and VGM Style Scores.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AstraZeneca PLC (AZN) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research